Clinical Trials Sponsored by SCRI Development Innovations, LLC

Total 198 results

SCRI Development Innovations, LLC

Withdrawn

iCORE: Collaborative Orthopedics Outcomes Registry (iCORE)

Arthroplasty, Replacement, Knee | Arthroplasty, Replacement, Hip

United States
SCRI Development Innovations, LLC

Withdrawn

Sarah Cannon Outcomes Registry

Oncology

United States
SCRI Development Innovations, LLC

Terminated

SCRI Tissue Testing Registry

Melanoma | Lymphoma | Multiple Myeloma | Myelodysplastic Syndrome

United States
SCRI Development Innovations, LLC

Terminated

A Study of CPX-351 (Vyxeos™) With Quizartinib for the Treatment of FLT3-ITD Mutation-Positive Acute Myeloid Leukemia

Leukemia, Myeloid, Acute

United States
SCRI Development Innovations, LLC

Completed

Utilization of the OncoCEE™ Platform to Evaluate Selected Biomarker Alterations in CTCs Isolated From Patients With MBC

Metastatic Breast Cancer

United States
Morphotek
SCRI Development Innovations, LLC

Completed

Dose Escalation Study MORAb-066 Targeting Tissue Factor (TF)-Expressing Malignancies Including Breast, Pancreatic, Colorectal, NSCLC

Adenocarcinoma | Breast Cancer | Carcinoma, Non-Small-Cell Lung | Colorectal Cancer | Pancreatic Cancer

United States
SCRI Development Innovations, LLC
Celgene

Terminated

Nab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial Carcinoma

Transitional Cell Carcinoma | Bladder Cancer | Urothelial Carcinoma

United States
SCRI Development Innovations, LLC
Novartis

Completed

INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme

Renal Cell Carcinoma | Colorectal Cancer | Glioblastoma Multiforme | Gliosarcoma

United States
SCRI Development Innovations, LLC
Pfizer

Completed

Irinotecan, Carboplatin, and Sunitinib in First Line Extensive-Stage Small Cell Lung Cancer

Small Cell Lung Cancer

United States
Medicure
SCRI Development Innovations, LLC

Completed

Shortened Aggrastat® Versus Integrilin in Percutaneous Coronary Intervention (SAVI-PCI)

Myocardial Infarction | Unstable Angina | Acute Coronary Syndromes

United States
SCRI Development Innovations, LLC
Novartis

Completed

Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme

Glioblastoma Multiforme

United States
Medicure
SCRI Development Innovations, LLC

Withdrawn

Aggrastat Truncated Length Against Standard Therapies in Percutaneous Coronary Intervention (ATLAST-PCI)

Myocardial Infarction | Percutaneous Coronary Intervention | Unstable Angina | Acute Coronary Syndromes
SCRI Development Innovations, LLC
Novartis

Terminated

Safety/Efficacy Study of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

United States
SCRI Development Innovations, LLC
Novartis

Completed

Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal Tumor

Gastrointestinal Stromal Tumor

United States
SCRI Development Innovations, LLC
GlaxoSmithKline

Completed

Ofatumumab for Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
SCRI Development Innovations, LLC
Bayer

Completed

Radiation Therapy and Temozolomide Followed by Temozolomide Plus Sorafenib for Glioblastoma Multiforme

Glioblastoma Multiforme

United States
SCRI Development Innovations, LLC
Amgen

Completed

Carboplatin, Pemetrexed, and Panitumumab in Patients With Advanced Non-Squamous K-ras Wild Type NSCLC

Non-Small-Cell Lung Cancer

United States
SCRI Development Innovations, LLC
Novartis

Completed

LBH589 in Combination With Capecitabine Plus/Minus (±) Lapatinib in Breast Cancer Patients

Breast Cancer

United States
SCRI Development Innovations, LLC
Novartis

Completed

Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer

Metastatic Breast Cancer

United States
SCRI Development Innovations, LLC
Bayer

Completed

Adjuvant Doxorubicin/Cyclophosphamide and Paclitaxel Plus Sorafenib Breast Cancer

Breast Cancer

United States
SCRI Development Innovations, LLC
GlaxoSmithKline

Completed

Topotecan and Carboplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer

Carcinoma, Small Cell

United States
SCRI Development Innovations, LLC
GlaxoSmithKline

Completed

Topotecan Plus Paclitaxel and Carboplatin in the Initial Treatment of Advanced Ovarian and Primary Peritoneal Carcinoma

Ovary Cancer
SCRI Development Innovations, LLC
GlaxoSmithKline

Completed

Weekly Topotecan in the Second-Line Treatment of Small Cell Lung Cancer

Lung Cancer
SCRI Development Innovations, LLC
Pfizer

Withdrawn

Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic Lymphoma Kinase Positive (ALK+) Non-small Cell Lung Cancer (NSCLC) Who Progressed on Single-agent Lorlatinib (NSCLC)

Lung Cancer | Non-small Cell Lung Cancer

United States
SCRI Development Innovations, LLC
Ipsen

Terminated

Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres

Gastrointestinal Neoplasms | Neuroendocrine Tumors | Carcinoid Tumors

United States
SCRI Development Innovations, LLC
Celgene

Completed

Study of Nab-Paclitaxel and Ramucirumab as Second-line Treatment for Patients With Metastatic Gastroesophageal Cancer

Gastroesophageal Cancer

United States
SCRI Development Innovations, LLC
GlaxoSmithKline

Terminated

Pazopanib/Doxil in Adv Relapsed Plat Sensitive or Resistant Ovarian, Fallopian or Primary Peritoneal Adenocarcinoma

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Carcinoma

United States
AstraZeneca
SCRI Development Innovations, LLC

Completed

A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC)

Papillary Renal Cell Cancer

United States, Canada, United Kingdom, Spain
SCRI Development Innovations, LLC
Novartis

Completed

Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer

Breast Cancer

United States
SCRI Development Innovations, LLC
Sanofi

Completed

5-FU, Aflibercept, and Radiation (RT) for Preoperative and Postoperative Patients With Stage II/III Rectal Cancer

Rectal Cancer

United States
SCRI Development Innovations, LLC
Pfizer

Completed

Neoadjuvant Sunitinib With Paclitaxel/Carboplatin in Patients With Triple-Negative Breast Cancer

Breast Cancer

United States
SCRI Development Innovations, LLC
GlaxoSmithKline

Terminated

Study of 5-FU, Oxaliplatin, & Lapatinib Combined With Radiation Therapy to Treat HER2 Positive Esophagogastric Cancer

HER2 Positive Esophagogastric Cancer

United States
SCRI Development Innovations, LLC
Celgene

Completed

A Trial of Amrubicin and Carboplatin With Pegfilgrastim in Patients With Extensive-Stage Small Cell Lung Cancer

Extensive-Stage Small Cell Lung Cancer

United States
SCRI Development Innovations, LLC
Amgen

Completed

A Retrospective Cohort Study of Infusion Reactions Due to Vectibix

Infusion Reaction

United States
SCRI Development Innovations, LLC
GlaxoSmithKline

Completed

Pazopanib in Previously Treated Patients With Metastatic Renal Cell Carcinoma

Renal Cell Carcinoma

United States
SCRI Development Innovations, LLC
Bayer

Completed

Sorafenib and Bortezomib Treatment for Relapsed or Refractory Multiple Myeloma Patients

Multiple Myeloma

United States
SCRI Development Innovations, LLC
Novartis

Withdrawn

A Study of Panobinostat (LBH589) as Second-Line Therapy in Patients With Chronic Graft-Versus-Host Disease

Chronic Graft-Versus-Host Disease

United States
SCRI Development Innovations, LLC
Bayer

Completed

Study of the Pharmacokinetics/Safety of Sorafenib + Capecitabine in Advanced Solid Tumors

Refractory Malignancy

United States
SCRI Development Innovations, LLC
Biogen

Completed

Ifosfamide/Carboplatin/Etoposide/Rituxan Followed by Zevalin in Relapsed/Refractory Intermediate Grade B-Cell Lymphoma

Non-Hodgkins Lymphoma

United States
SCRI Development Innovations, LLC
GlaxoSmithKline

Completed

Weekly Topotecan in Patients Treated for Metastatic Colorectal Cancer

Colon Cancer

United States
SCRI Development Innovations, LLC
Novartis

Completed

PTK787/ZK222584 With Bevacizumab in Patients With Refractory and/or Advanced Malignancies

Advanced Malignancies | Refractory Malignancy

United States
SCRI Development Innovations, LLC
Amgen

Completed

Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers

Neuroendocrine Cancer

United States
SCRI Development Innovations, LLC
Celgene

Completed

Trial of Amrubicin as Treatment for Patients With HER2-Negative Metastatic Breast Cancer

Metastatic Breast Cancer

United States
SCRI Development Innovations, LLC
Bayer

Completed

Sorafenib/Erlotinib Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer

United States
SCRI Development Innovations, LLC
Novartis

Completed

LBH589 Treatment for Refractory Clear Cell Renal Carcinoma

Renal Cell Carcinoma

United States
SCRI Development Innovations, LLC
Sanofi

Completed

Trastuzumab and Oxaliplatin in Patients With Metastatic Breast Cancer

Breast Cancer

United States
SCRI Development Innovations, LLC
Pfizer

Completed

A Trial of Single Agent Axitinib as Maintenance Therapy for Patients With First Line Metastatic Colorectal Cancer (mCRC)

Colorectal Cancer

United States
SCRI Development Innovations, LLC
Novartis

Completed

Trial of Erlotinib and BKM120 in Patients With Advanced Non Small Cell Lung Cancer Previously Sensitive to Erlotinib

Non Small Cell Lung Cancer

United States
SCRI Development Innovations, LLC
Novartis

Withdrawn

Cabazitaxel and BKM120 in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel

Advanced Prostate Cancer

United States
SCRI Development Innovations, LLC
Amgen

Completed

FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only

Colorectal Cancer

United States

Clinical Trials Sponsored by SCRI Development Innovations, LLC

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Jamaica

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations